Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
March 3, 2026
Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis
SY
Shang Yue
Dalian Medical University
YP
Yan-Gui Peng
Dalian Medical University
YW
Yan Wang
Dalian Ocean University
Ver todo
Puntos clave
Anwulignan inhibits the IL-36R/TLR9 signaling pathway, reducing hepatic fibrosis.
The study observes a notable decrease in fibrosis markers with Anwulignan treatment.
This involves an analysis using animal models to explore therapeutic effects.
Highlighting the potential role of Anwulignan, further validation in human models is warranted.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis | Synapse
Cite This Study
Copy
Yue et al. (Fri,) studied this question.
synapsesocial.com/papers/69a767eebadf0bb9e87e2ed0
https://doi.org/https://doi.org/10.1016/j.phymed.2026.157931